This significant funding will fuel the continued expansion of Glytec’s platform, including its flagship Glucommander® SaaS solution, accelerate the development of innovative new technologies to address the growing global health crisis of diabetes and related co-morbidities, and support the continued rapid response to upcoming CMS quality measures that will hold health systems accountable for inpatient glycemic control.

Funding to drive development of permanent bioelectronic pacemaker following promising clinical data.

Clinical progress, industrial partnerships, and global recognition drive momentum in rehabilitation, personal mobility, and humanoid robotics. The new agreement with Renault accelerates commercialization and advances Wandercraft’s global robotics footprint.